The Role of Interferon in Premature Atherosclerosis in Systemic Lupus Erythematosus Patients
DOI:
https://doi.org/10.12970/2310-9874.2014.02.02.6Keywords:
Interferon, Premature atherosclerosis, Systemic Lupus Erythematosus.Abstract
Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disease associated with significant cardiovascular morbidity and mortality. Studies have established that patients with SLE develop accelerated atherosclerosis related to endothelial cell dysfunction and acute vascular events not explained by Framingham risk score risk stratification. In this article, we closely explore the role of interferons in endothelial cell apoptosis and vascular dysfunction. Understanding the mechanisms responsible for the significant increase in atherosclerotic cardiovascular complications in patients with SLE, and the role of type I interferon may serve as the basis for developing target therapy with pharmacological agents.
References
Toth P, Shammas N, Dippel E, Foreman B. Cardiovascular disease. In R. E. Rakel, & D. P. Rakel (Eds.), Textbook of family medicine 2011; pp. 479-82.
Frieri M. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. Curr Allergy Asthma Rep 2012; 12: 25-32. http://dx.doi.org/10.1007/s11882-011-0236-1
Westerweel P, Luyten R, Koomans H, Derksen R, Verhaar M. Premature Atherosclerosis-Cardiovascular Disease in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1384-96. http://dx.doi.org/10.1002/art.22568
Ferrieres J. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins. Am J Cardiovasc Drugs 2009; 9: 109-15. http://dx.doi.org/10.1007/BF03256582
Denny M, Thacker S, Mehta H, et al. Interferon-α promotes abnormal vasculogenisis in lupus: a potential pathway for premature atherosclerosis. Blood 2007; 110: 2907-15. http://dx.doi.org/10.1182/blood-2007-05-089086
Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol 2013; 110: 228-32. http://dx.doi.org/10.1016/j.anai.2012.12.010
Elkon K, Stone V. Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res 2011; 31: 803-12. http://dx.doi.org/10.1089/jir.2011.0045
Hunt M. Interferon," Microbiology and Immunology On-line. University of South Carolina School of Medicine, 2009 May 5. Available from http://pathmicro.med.sc.edu/mhunt/ interferon.htm.
Li J, Fu Q, Cui H, et al. Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus. Arthritis Rheum 2011; 63: 492-502. http://dx.doi.org/10.1002/art.30165
Kahlenberg JM, Thacker SG, Berthier CC, Cohen CD, Kretzler M, Kaplan MJ. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 2011; 187: 6143-56. http://dx.doi.org/10.4049/jimmunol.1101284
Gracie J, Robertson S, McInnes I. Interleukin- 18. J Leukoc Biol 2003; 73: 213-24. http://dx.doi.org/10.1189/jlb.0602313
Vlachopoulos C, Ioakeimidis N, Aznaouridis K, et al. Association of interleukin-18 levels with global arterial function and early structural changes in men without cardiovascular disease. Am J Hypertens 2010; 23: 351-7. http://dx.doi.org/10.1038/ajh.2009.256
Knight J, Kaplan M. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol 2013; 25: 597-605. http://dx.doi.org/10.1097/BOR.0b013e328363eba3
Thacker S, Berthier C, Mattinzoli D, Rastaldi M, Kretzler M, Kaplan M. The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010; 187: 4457-69. http://dx.doi.org/10.4049/jimmunol.1001782
Frieri M, Samih M, Liu H, Balsam L, Rubinstein S. Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J Nephrol 2012; 25: 1041-6. http://dx.doi.org/10.5301/jn.5000091
Kaplan MJ, Salmon JE. How does interferon-α insult the vasculature? Let me count the ways. Arthritis Rheum 2011; 63: 334-6. http://dx.doi.org/10.1002/art.30161
Frieri M. Complement related diseases. Allergy Asthma Proc 2002; 25: 319-24.
Belot A, Cimaz R. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J 2012; 10: 21. http://dx.doi.org/10.1186/1546-0096-10-21
Gerrity RG, Naito HK, Richardson M, Schwartz CJ. Dietary induced atherogenesis in swine: morphology of the intima in prelesion stages. Am J Pathol 1979; 95: 775-92.
Goossens P, Gijbels J, Zernecke A, et al. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 2010; 12: 142-53. http://dx.doi.org/10.1016/j.cmet.2010.06.008
McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012; 64: 3666-76. http://dx.doi.org/10.1002/art.34632
Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti–interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013; 65: 1011-21. http://dx.doi.org/10.1002/art.37824
Argos Therapeutics Presents Positive Phase 1a Data for AGS-009 in Patients with Lupus at 2012 EULAR Congress: Demonstrates Dose-Proportional Neutralization of Interferon-Alpha Activity. Argos Therapeutics, Durham, NC, 2012.
Sullivan T, Atiee G, Bhagat L, et al. A novel toll-like receptor antagonist for autoimmune and inflammatory diseases: safety and pharmacodynamics in a multiple-dose phase 1 clinical trial. Keystone Symposia Meeting: Immunoregulatory Networks, 2011.
Kahlenberg JM, Lundberg KC, Kertesy SB, Qu Y, Dubyak GR. Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-kappaB-driven protein synthesis. J Immunol 2005; 175: 7611-22. http://dx.doi.org/10.4049/jimmunol.175.11.7611
Hurst J, Prinz N, Lorenz M, et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009; 214: 683-91. http://dx.doi.org/10.1016/j.imbio.2008.12.003
Komatsuda A, Wakui H, Ozawa M, et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008; 152: 482-7. http://dx.doi.org/10.1111/j.1365-2249.2008.03646.x
Zhu F, Yu D, Kandimalla ER, La Monica N, Agrawal S. Treatment with IMO-3100, a novel TLR7 and TLR9 dual antagonist, inhibits disease development in lupus prone NZBW/F1 mice. Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, MA 02139, USA.
Zagury D, Le Buanec H, Mathian A, et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009; 106: 5294-9. http://dx.doi.org/10.1073/pnas.0900615106
Ichikawa HT, Conley T, Muchamuel T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Athritis Rheum 2012; 64: 493-503. http://dx.doi.org/10.1002/art.33333
Pipeline: Autoimmunity/Inflammation. [internet] 2011. [cited 2013 Nov 4]. Available from http://www.dynavax.com/ autoimmunity.html
Postal M, Costallat LTL, Appenzeller S. Biological therapy in systemic lupus erythematosus. Int J Rheumatol 2012; 2012: 578641. http://dx.doi.org/10.1155/2012/578641
Kirou KA, Kalliolias JD. A new tool for detection of type I interferon activation in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: 138. http://dx.doi.org/10.1186/ar3114
Crow MK. Interferon-a: new target for therapy in systemic lupus erythematosus? Arthritis Rheum 2003; 48: 2396-401. http://dx.doi.org/10.1002/art.11226
Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity. Arthritis Rheum 2009; 60: 3098-107. http://dx.doi.org/10.1002/art.24803
